康柏西普联合玻璃体切除术治疗进展型增殖期糖尿病视网膜病变的疗效

The effect of conbercept combined with vitrectomy in the treatment of progressive proliferative diabetic retinopathy

目的:分析康柏西普联合玻璃体切除术治疗进展型增殖期糖尿病视网膜病变(DR)的疗效。方法:选取进展型增殖期DR患者84例,随机分为对照组和研究组各42例。对照组行传统玻璃体切除术,研究组行康柏西普联合玻璃体切除术。比较两组手术效果及预后。结果:术前视力、黄斑厚度两组比较差异无统计学意义(P>0.05)。手术后,研究组视力、黄斑厚度改善幅度大于对照组;且研究组手术时间,术中出血、电凝、硅油及医源性裂孔发生率均低于对照组;研究组术后前房积血、玻璃体腔再出血发生率低于对照组(P<0.05)。结论:康柏西普联合玻璃体切除术治疗进展型增殖期DR,可降低术中医源性损伤风险,手术预后效果较好。

Objective:To analyze the efficacy of conbercept combined with vitrectomy in the treatment of progressive proliferative diabetic retinopathy.Methods:A total of 84 patients with progressive proliferative diabetic retinopathy were selected and randomly divided into a control group and a study group with 42 cases each.The control group underwent traditional vitrectomy while the study group underwent conbercept combined with vitrectomy.The surgical effect and prognosis were compared between the two groups.Results:There were no statistically significant differences in preoperative visual acuity and macular thickness between the two groups before treatment(P>0.05).The improvement in the visual acuity and macular thickness was significant better and the operation time,intraoperative bleeding,electrocoagulation,silicone oil and iatrogenic holes were significantly lower in the study group than the control group after the operation(P<0.05).The incidence of postoperative anterior chamber hemorrhage and vitreous cavity rebleeding was significantly decreased in the study group.Conclusion:Conbercept combined with vitrectomy for the treatment of patients with progressive proliferative diabetic retinopathy can reduce the risk of iatrogenic injury during the operation with good prognosis.